Portal:COVID-19/CoveredPWs
From WikiPathways
(Difference between revisions)
| Line 15: | Line 15: | ||
| Activation of NLRP3 Inflammasome by SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | | Activation of NLRP3 Inflammasome by SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | ||
|- | |- | ||
| - | | SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | + | | SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor :<br/> Molecular mechanisms and potential therapeutic target || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress |
|- | |- | ||
| COVID-19 AOP || [https://www.wikipathways.org/index.php/Pathway:WP4891 WP4891] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | | COVID-19 AOP || [https://www.wikipathways.org/index.php/Pathway:WP4891 WP4891] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | ||
| Line 23: | Line 23: | ||
| LDLRAD4 pathway in COVID-19 || [https://www.wikipathways.org/index.php/Pathway:WP4904 WP4904] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | | LDLRAD4 pathway in COVID-19 || [https://www.wikipathways.org/index.php/Pathway:WP4904 WP4904] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | ||
|- | |- | ||
| - | | Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4936 WP4936] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress | + | | Overview of perturbations to host-cell autophagy,<br/> induced by distinct proteins of SARS-CoV-2 || [https://www.wikipathways.org/index.php/Pathway:WP4936 WP4936] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress |
|- | |- | ||
|} | |} | ||
Revision as of 19:19, 9 September 2020
The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2).
| Title | Links WP | Category | Status |
|---|---|---|---|
| SARS-CoV-2 and COVID-19 Pathway | WP4846 | SARS-CoV-2 Pathways | Approved |
| Hijack of Ubiquitination by SARS-CoV-2 | WP4860 | SARS-CoV-2 Pathways | Approved |
| Type I Interferon Induction and Signaling During SARS-CoV-2 Infection | WP4868 | SARS-CoV-2 Pathways | In Progress |
| COVID-19, thrombosis and anticoagulation | WP4927 | SARS-CoV-2 Pathways | In Progress |
| Activation of NLRP3 Inflammasome by SARS-CoV-2 | WP4876 | SARS-CoV-2 Pathways | In Progress |
| SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target | WP4883 | SARS-CoV-2 Pathways | In Progress |
| COVID-19 AOP | WP4891 | SARS-CoV-2 Pathways | In Progress |
| nsp9/nsp10-mediated SARS-CoV-2 pathogenesis | WP4884 | SARS-CoV-2 Pathways | In Progress |
| LDLRAD4 pathway in COVID-19 | WP4904 | SARS-CoV-2 Pathways | In Progress |
| Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 | WP4936 | SARS-CoV-2 Pathways | In Progress |
